首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Clinical Drug Investigation

Clinical Drug Investigation杂志,由Springer International Publishing出版,于1989年创刊,Monthly,出版语言English,ISSN:1173-2563,E-ISSN:1179-1918。

投稿咨询
Clinical Drug Investigation
Clinical Drug Investigation
Clinical Drug Investigation
SCI SCIE

杂志介绍

JCR分区
Q2
中科院分区
3区
影响因子
3.1
CiteScore
5.2
期刊收录
SCI、SCIE

Clinical Drug Investigation(中文译名:《临床药物调查》),ISSN:1173-2563,EISSN:1179-1918,是Springer International Publishing出版的国际性学术期刊,创刊于1989年,以Monthly形式稳定发行,2026年总发文量约81篇。该刊采用非OA开放访问,学科归属为医学 - 药学。该刊是医学、药学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达3.1,2025年期刊CiteScore为5.2,2025年期刊自引率约0%,在中科院期刊分区体系中位列医学大类3区,在所属学科领域具备高学术影响力与国际认可度。Clinical Drug Investigation长期聚焦医学、药学及相关产业的技术应用前沿,平均审稿周期较慢,6-12周,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、药学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,USAJapan、CHINA MAINLAND、Italy、England、Spain、New Zealand等为核心发文国家与地区;SPRINGER NATSPRINGER NATURE、CIBER - CENTRO DE INVESTIGACION BIOMEDICA EN RED、JOHNSON & JOHNSON、KITASATO UNIVERSITY、UNIVERSITY OF BARCELONA、UNIVERSITY OF FLORENCE等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
3区
PHARMACOLOGY & PHARMACY 药学
3区

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
3区
PHARMACOLOGY & PHARMACY 药学
3区

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
3区
PHARMACOLOGY & PHARMACY 药学
3区

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:PHARMACOLOGY & PHARMACY SCIE Q2 163 / 356

54.4

学科:PHARMACOLOGY & PHARMACY SCIE Q2 157 / 356

56.04

2024-2025年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:PHARMACOLOGY & PHARMACY SCIE Q2 164 / 352

53.6

学科:PHARMACOLOGY & PHARMACY SCIE Q2 140 / 353

60.48


中国学者近期发文

1
Effectiveness of Dexmedetomidine and Sufentanil in Preventing Adverse Reactions to Carboprost Tromethamine During Cesarean Section with Noninvasive Cardiac System Monitorin

Author:Li, Jing; Xiang, Bo; Lei, Xiaofeng; Yu, Jin

Journal: CLINICAL DRUG INVESTIGATION. 2026; Vol. 46, Issue 5, pp. 551-559. DOI: 10.1007/s40261-026-01547-x

2
Pharmacokinetics, Safety Profile, and Tolerability of MN-08 Tablets after Single and Multiple Ascending Doses in Healthy Chinese Volunteer

Author:Yang, Enyue; Chen, Mingxin; Wu, Mingji; Dong, Qi; Li, Jinhua; Xu, Honglan; Qu, Baoju; Zhang, Huazi; Jin, Zhehu; Li, Guantong; Jing, Mei; Zhang, Zaijun; Zhang, Gaoxiao; Piao, Hongxin

Journal: CLINICAL DRUG INVESTIGATION. 2026; Vol. 46, Issue 4, pp. 391-406. DOI: 10.1007/s40261-026-01522-6

3
Global Long-Term Cost Effectiveness of Newer Antidiabetic Drugs for Type 2 Diabetes Mellitus: A Systematic Revie

Author:Li, Dan; Smith, Alesha; Marra, Carlo A

Journal: CLINICAL DRUG INVESTIGATION. 2026; Vol. 46, Issue 4, pp. 359-376. DOI: 10.1007/s40261-026-01530-6

4
Cost-Effectiveness Analysis of PI3K Inhibitors for Relapsed or Refractory Follicular Lymphoma in China: A Comparison Between Linperlisib and Duvelisi

Author:Bai, Xuefei; Shao, Rongjie; He, Xiaoning

Journal: CLINICAL DRUG INVESTIGATION. 2026; Vol. , Issue , pp. -. DOI: 10.1007/s40261-026-01532-4

5
Comparison of the Efficacy of Denosumab and Alendronate in Improving Bone Mineral Density in Osteoporosis Patients and High-Risk Populations: A Systematic Review and Meta-Analysi

Author:Zhu, Kejia; Li, Hang; Zhang, Hui; Zhou, Zongke; Shen, Bin; Nie, Yong

Journal: CLINICAL DRUG INVESTIGATION. 2026; Vol. , Issue , pp. -. DOI: 10.1007/s40261-025-01521-z

6
A Single-Center, Randomized, Open-Label, Two-Formulation, Two-Sequence, Two-Period Crossover Study to Evaluate the Bioequivalence of Two Eltrombopag Olamine Tablets (25 mg) in Healthy Chinese Subjects in the Fed Stat

Author:Wu, Keyi; Ren, Qin; Wang, Yanli; Zhou, Yannan; Liu, Zhengzhi; Cheng, Yang; Deng, Qiaohuan; Cui, Yingzi; Yang, Haimiao

Journal: CLINICAL DRUG INVESTIGATION. 2026; Vol. , Issue , pp. -. DOI: 10.1007/s40261-026-01528-0

7
Population Pharmacokinetics of SCT510 (a Bevacizumab Biosimilar) and Avastin® in Healthy Subjects and Patients with Non-squamous Non-small Cell Lung Cance

Author:Hong, Qianqian; Jiao, Yuhuan; Li, Dongyang; Ma, Hongyun; Wu, Kun; Xie, Liangzhi

Journal: CLINICAL DRUG INVESTIGATION. 2026; Vol. , Issue , pp. -. DOI: 10.1007/s40261-025-01518-8

8
Risk of Ophthalmotoxicity Associated with Antibody-Drug Conjugates: A Systematic Review and Meta-analysi

Author:Feng, Xin; Yu, Xiaoxia; Yang, Shan; Yuan, Guosen; Huang, Min; He, Zhichao; Wu, Junyan

Journal: CLINICAL DRUG INVESTIGATION. 2025; Vol. , Issue , pp. -. DOI: 10.1007/s40261-025-01447-6

9
Economic Evaluation of Penpulimab Plus Paclitaxel and Carboplatin Combination Therapy as First-Line Treatment for Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer in Chin

Author:Han, Meng; Jung, Hye-In; Chen, Yong-Fa; Lee, Eui-Kyung

Journal: CLINICAL DRUG INVESTIGATION. 2025; Vol. , Issue , pp. -. DOI: 10.1007/s40261-025-01439-6

10
Dose-Dependent Relationship Between Long-Term Metformin Use and the Risk of Diabetic Retinopathy: A Population-Based Cohort Stud

Author:Li, Yu-Ching; Huang, Kuang-Hua; Yang, Yih; Gau, Shuo-Yan; Tsai, Tung-Han; Lee, Chien-Ying

Journal: CLINICAL DRUG INVESTIGATION. 2025; Vol. , Issue , pp. -. DOI: 10.1007/s40261-025-01421-2


在线咨询

Clinical Drug Investigation

国际简称:CLIN DRUG INVEST参考译名:临床药物调查

年发文量:81 CiteScore:5.2 是否预警:否 Gold OA文章占比:44.64% 研究类文章占比:67.90%

杂志社联系方式:ADIS INT LTD, 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND, NEW ZEALAND, 1311

Clinical Drug Investigation